JP7789303B2 - 上皮バリア機能障害の治療のためのタンパク質 - Google Patents

上皮バリア機能障害の治療のためのタンパク質

Info

Publication number
JP7789303B2
JP7789303B2 JP2019554976A JP2019554976A JP7789303B2 JP 7789303 B2 JP7789303 B2 JP 7789303B2 JP 2019554976 A JP2019554976 A JP 2019554976A JP 2019554976 A JP2019554976 A JP 2019554976A JP 7789303 B2 JP7789303 B2 JP 7789303B2
Authority
JP
Japan
Prior art keywords
seq
protein
amino acid
acid sequence
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516615A5 (cg-RX-API-DMAC7.html
JP2020516615A (ja
Inventor
アンドリュー ウォニ ハン
アンドリュー ホイットマン グッドイヤー
タルンメート グジュラール
トッド ザチャリー デサンティス
カリム ダバグ
トシヒコ タケウチ
イェ ジン
美知 泉
ステファニー バナス
Original Assignee
ジェネヴィーヴ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネヴィーヴ インコーポレイテッド filed Critical ジェネヴィーヴ インコーポレイテッド
Publication of JP2020516615A publication Critical patent/JP2020516615A/ja
Publication of JP2020516615A5 publication Critical patent/JP2020516615A5/ja
Priority to JP2023208379A priority Critical patent/JP2024037834A/ja
Application granted granted Critical
Publication of JP7789303B2 publication Critical patent/JP7789303B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
JP2019554976A 2017-04-07 2018-04-06 上皮バリア機能障害の治療のためのタンパク質 Active JP7789303B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023208379A JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762482963P 2017-04-07 2017-04-07
US62/482,963 2017-04-07
US201762607706P 2017-12-19 2017-12-19
US62/607,706 2017-12-19
US201762611334P 2017-12-28 2017-12-28
US62/611,334 2017-12-28
PCT/US2018/026447 WO2018187682A1 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023208379A Division JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Publications (3)

Publication Number Publication Date
JP2020516615A JP2020516615A (ja) 2020-06-11
JP2020516615A5 JP2020516615A5 (cg-RX-API-DMAC7.html) 2021-05-13
JP7789303B2 true JP7789303B2 (ja) 2025-12-22

Family

ID=63710147

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019554976A Active JP7789303B2 (ja) 2017-04-07 2018-04-06 上皮バリア機能障害の治療のためのタンパク質
JP2023208379A Pending JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023208379A Pending JP2024037834A (ja) 2017-04-07 2023-12-11 上皮バリア機能障害の治療のためのタンパク質

Country Status (12)

Country Link
US (3) US10251933B2 (cg-RX-API-DMAC7.html)
EP (1) EP3606542A4 (cg-RX-API-DMAC7.html)
JP (2) JP7789303B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200003821A (cg-RX-API-DMAC7.html)
CN (1) CN110769844B (cg-RX-API-DMAC7.html)
AU (2) AU2018248324B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059354A1 (cg-RX-API-DMAC7.html)
IL (1) IL269853A (cg-RX-API-DMAC7.html)
MX (2) MX393998B (cg-RX-API-DMAC7.html)
SG (1) SG11201909334TA (cg-RX-API-DMAC7.html)
TW (1) TWI797116B (cg-RX-API-DMAC7.html)
WO (1) WO2018187682A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
EP3773644A4 (en) * 2018-04-06 2021-06-02 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
JP2022512639A (ja) * 2018-10-09 2022-02-07 セカンド ゲノム インコーポレイテッド 上皮バリア機能障害の治療に有効なタンパク質を送達するためのラクトコッカス・ラクティス発現系
WO2021035129A1 (en) * 2019-08-21 2021-02-25 Astrazeneca Collaboration Ventures, Llc Use of brazikumab to treat crohn's disease
US11666629B2 (en) * 2020-01-10 2023-06-06 National Taipei University Of Technology Peptide interacting with toll-like receptor 2 and the composition comprising the same
CN113773364B (zh) * 2021-08-25 2023-04-28 无锡市儿童医院 小分子肽及其制备方法和应用
WO2024098026A2 (en) * 2022-11-04 2024-05-10 Mink Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014534957A (ja) 2011-10-07 2014-12-25 ジーティー バイオロジクス エルティーディーＧｔ Ｂｉｏｌｏｇｉｃｓ Ｌｔｄ 栄養学的及び医学的用途のためのプロバイオティクスとして使用するための細菌

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ES2568938T3 (es) 2009-04-28 2016-05-05 Vanderbilt University Composiciones y procedimientos de tratamiento de trastornos que implican apoptosis de células epiteliales
JP2014093482A (ja) 2012-11-06 2014-05-19 Toshiba Corp 固体撮像装置の製造方法および固体撮像装置
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015014973A2 (en) * 2013-07-31 2015-02-05 Institut National De La Recherche Agronomique Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions
PT3307288T (pt) * 2015-06-15 2019-10-17 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) * 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
WO2018223051A1 (en) 2017-06-02 2018-12-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014534957A (ja) 2011-10-07 2014-12-25 ジーティー バイオロジクス エルティーディーＧｔ Ｂｉｏｌｏｇｉｃｓ Ｌｔｄ 栄養学的及び医学的用途のためのプロバイオティクスとして使用するための細菌

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
hypothetical protein [Roseburia hominis], DATABASE NCBI Protein [online] accession No.WP_014079420, 2013年, https://www.ncbi.nlm.nih.gov/protein/WP_014079420.1?report=genbank&log$=prottop&blast_rank=1&RID=7VWKWEG4013

Also Published As

Publication number Publication date
US20180289770A1 (en) 2018-10-11
US20200148728A1 (en) 2020-05-14
AU2018248324A1 (en) 2019-10-31
MX2019012051A (es) 2020-02-12
CN110769844A (zh) 2020-02-07
SG11201909334TA (en) 2019-11-28
WO2018187682A1 (en) 2018-10-11
AU2018248324B2 (en) 2023-02-09
MX2022008842A (es) 2022-08-02
TW201841649A (zh) 2018-12-01
JP2020516615A (ja) 2020-06-11
US20240066095A1 (en) 2024-02-29
EP3606542A1 (en) 2020-02-12
US10251933B2 (en) 2019-04-09
US11207376B2 (en) 2021-12-28
IL269853A (en) 2019-11-28
EP3606542A4 (en) 2021-01-20
JP2024037834A (ja) 2024-03-19
MX393998B (es) 2025-03-24
TWI797116B (zh) 2023-04-01
CN110769844B (zh) 2025-01-21
KR20230144097A (ko) 2023-10-13
AU2023202844A1 (en) 2023-07-06
CA3059354A1 (en) 2018-10-11
KR20200003821A (ko) 2020-01-10

Similar Documents

Publication Publication Date Title
JP7789303B2 (ja) 上皮バリア機能障害の治療のためのタンパク質
US12168677B2 (en) Proteins for the treatment of epithelial barrier function disorders
US12186364B2 (en) Proteins for the treatment of epithelial barrier function disorders
US11505583B2 (en) Proteins for the treatment of epithelial barrier function disorders
US20210380994A1 (en) Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders
US11666627B2 (en) Proteins for the treatment of epithelial barrier function disorders
WO2019213105A1 (en) Methods and compositions involving plantaricin ef (plnef)
US12371456B2 (en) Proteins for the treatment of epithelial barrier function disorders
Lei et al. Salmonella virulence factor SsrAB regulated factor modulates inflammatory responses by enhancing the activation of NF-κB signaling pathway
KR102903277B1 (ko) 상피 장벽 기능 장애 치료용 단백질
Heeney The Bacterial Protein Targeted by the Class IIb Bacteriocin Plantaricin EF and the Potential of Plantaricin EF to Improve Metabolic Health

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191029

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191030

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230214

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231226

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251125

R150 Certificate of patent or registration of utility model

Ref document number: 7789303

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150